A Randomized, Open-label, Fed, Single Dose, Two-way Crossover Study to Evaluate the Pharmacokinetics and Safety of "BR3409" and Co-administration of "BR3409-1" and "BR3409-2" in Healthy Volunteers
Latest Information Update: 26 Mar 2025
At a glance
- Drugs BR 3409 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
- 26 Mar 2025 New trial record